News India Live, Digital Desk: Multibagger pharma company Sudarshan Pharma Industries shares will be in the eyes of investors on Monday. The company has released its final quarter and annual results of FY 2025, which recorded a significant increase in the company’s net sales and net profit.
According to the report, the company’s net sales value has increased by 19% to Rs 277 crore in the last quarter. At the same time, in the same period, the net profit has also gained a big increase of 43%, which has reached ₹ 7 crore. Talking about the entire financial year 2025, the net sales have increased by 9% to Rs 505 crore, while the net profit increased to Rs 16 crore.
In the last 5 years, Sudarshan Pharma Industries have given investors a return of more than 325%, which has proved to be a multibagger. However, on 2 May, the company’s stock fell 1.99% to close at ₹ 26.66. Currently, the company’s market value is around Rs 642 crore.
The company divided its shares into 10 pieces in November 2024, which reduced the face value of the share to ₹ 1 per share. In the last five years, the company’s profits have increased at a 37% annual rate.
Preparation for expansion abroad
Sudarshan Pharma Industries plans to strengthen their hold in domestic and international markets. Under this, the company is focusing on recycling and increasing the export of medicines in India, which can improve its profit margin.
The size of the Indian pharma industry was about $ 42 billion in 2021, which is expected to reach $ 50 billion by 2024 and by 2025 to about $ 66 billion. The sector is expected to reach $ 120 to 130 billion by 2030.
Palmistry Prediction: Inauspicious signs give cross marks in these places on the palm, know their effects
